A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Trial to Compare the Safety, Pharmacokinetics and Pharmacodynamics After Oral Administration of JW0302 to C2206 in Healthy Adult Subjects
Latest Information Update: 22 Mar 2024
At a glance
- Drugs JW 0302 (Primary)
- Indications Unspecified
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors JW Pharmaceutical
Most Recent Events
- 19 Mar 2024 Status changed from not yet recruiting to completed.
- 31 Mar 2023 New trial record